Inspira Technologies has received U.S. Patent approval for its low flow rates extracorporeal oxygenation system, key to penetrating the $20 billion advanced respiratory support market. This patent strengthens Inspira’s intellectual property portfolio and technological leadership in the field. The patent protects the core technology of the ART500 device, designed for patients needing respiratory support but not sick enough for traditional high-flow ECMO systems. Inspira’s CEO, Dagi Ben-Noon, emphasized the business implications and competitive advantage this patent provides. The protection is in place until 2043, with additional patents being pursued globally. This innovation positions Inspira as a leader in the life-support and MedTech landscape.

Read more at GlobeNewswire: Inspira Receives U.S. Patent Approval for the ART500 Core